Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C19 & UGT1A6 genetic polymorphisms and the impact on Valproic acid-induced weight gain in people with epilepsy: Prospective genetic association study.

Epilepsy research - 1 Nov 2021

Mani Balachandran, Nair Pradeep Pankajakshan, Sekhar Anamika, Kamalanathan Sadishkumar, Narayan Sunil K, Kesavan Ramasamy

Abstract excerpt

OBJECTIVES: To study the association between CYP2C19*2 (681 G > A) and UGT1A6*2 (552A > C) polymorphisms on Valproic acid (VPA)-induced weight gain in People with epilepsy (PWE). METHODS: We recruited PWE on VPA monotherapy and genotyped for CYP2C19 and UGT1A6 polymorphisms. Association between CYP2C19 polymorphism and weight gain was the primary outcome parameter. We followed them up monthly for six months and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epilepsy

Share to Genetic Association Studies

Share to Glucuronosyltransferase

Share to Polymorphism, Genetic

Share to Valproic Acid

Share to Weight Gain

Source

Identifiers

PMID: 34656038
DOI: 10.1016/j.eplepsyres.2021.106786

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19 & UGT1A6 genetic polymorphisms and the impact on Valproic acid-induced weight gain in people with epilepsy: Prospective genetic association study.PMID 34656038Read ↗

Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain.Semantic proximity Read ↗

Weight change, genetics and antiepileptic drugs.Semantic proximity Read ↗

Genetic risk, antiseizure medications, and lifestyle factors in epilepsy-associated obesity and overweight.Semantic proximity Read ↗

Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.Semantic proximity Read ↗

Weight gain with antipsychotic drugs: the role of the 5-HT2C receptor (HTR2C) and other genes.Semantic proximity Read ↗

Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid.Semantic proximity Read ↗

Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype.Semantic proximity Read ↗

Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gainSemantic proximity Read ↗

[Genetics of weight gain associated with antipsychotic medications].Semantic proximity Read ↗

Genetic variants of the serotonin system and weight change during clozapine treatment.Semantic proximity Read ↗

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism.Semantic proximity Read ↗

Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.